Company: NCEL
Filing Date: 2025-09-25
Form Type: F-1
Source: 0001213900-25-091697
Chunk: 128

Company: NewcelX Ltd.
Filing Date: 2025-09-25
Form: F-1
Chunk 128
---
holder to purchase up
to a specified maximum amount of Common Shares as set forth in the ELOC Purchase Agreement by delivering written notice to the Selling
Shareholder prior to the commencement of trading on any trading day. The purchase price of the Common Shares that the Company elects to
sell to the Selling Shareholder pursuant to the ELOC Purchase Agreement will be 95% of the volume-weighted average price of the Common
Shares during the applicable purchase date on which the Company has timely delivered written notice to the Selling Shareholder directing
it to purchase Common Shares under the Purchase Agreement.

In connection with the execution
of the ELOC Purchase Agreement, the Company agreed to issue a pre-funded warrant (the “Pre-Funded Warrant”), to purchase $250,000
in Common Shares to the Selling Shareholder as consideration for its irrevocable commitment to purchase the Common Shares upon the terms
and subject to the satisfaction of the conditions set forth in the ELOC Purchase Agreement.

Item 8. Exhibits and Financial Statement Schedules

Exhibits:

| Exhibit Number 
 2.1            
 2.2            |     | Exhibit Description                                                                                                                                                                                                                                                                                
 Agreement and Plan of Merger, dated as of November 4, 2024, by and among NLS Pharmaceutics Ltd., NLS Pharmaceutics (Israel) Ltd. and Kadimastem Ltd. (included as Annex A to the proxy statement/prospectus on Registration Statement on Form F-4 filed on September 3, 2025).                     
 Amendment No. 1 to Agreement and Plan of Merger, dated as of January 30, 2025, by and among NLS Pharmaceutics Ltd., NLS Pharmaceutics (Israel) Ltd. and Kadimastem Ltd. (included as Annex A to the proxy statement/prospectus on Registration Statement on Form F-4 filed on September 3, 2025).  |
|:---------------|:----|:---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 2.3            |     | Amendment No. 2 to Agreement and Plan of Merger, dated as of February 17, 2025, by and among NLS Pharmaceutics Ltd., NLS Pharmaceutics (Israel) Ltd. and Kadimastem Ltd. (included as Annex A to the proxy statement/prospectus on Registration Statement on Form F-4 filed on September 3, 2025). |
| 2.4            |     | Amendment No